Provided by Tiger Trade Technology Pte. Ltd.

Novo-Nordisk A/S

46.87
+0.13000.28%
Volume:1.65M
Turnover:77.60M
Market Cap:207.31B
PE:11.71
High:47.30
Open:47.04
Low:46.82
Close:46.74
52wk High:64.16
52wk Low:35.12
Shares:4.42B
Float Shares:3.19B
Volume Ratio:1.15
T/O Rate:0.05%
Dividend:1.72
Dividend Rate:3.67%
EPS(TTM):4.00
EPS(LYR):3.62
ROE:59.82%
ROA:18.73%
PB:6.37
PE(LYR):12.95

Loading ...

Live Longer and Better. Does Medicine's New Obsession Really Work? -- Barrons.com

Dow Jones
·
May 21

Singapore Court of Appeal Notes No Finding of Fraud Against KBP or Dr. Huang; Dispute with Novo Nordisk Undergoing Arbitration Proceedings

prnewswire
·
May 21

Novo Nordisk A/S Stock Rises Wednesday, Underperforms Market

Dow Jones
·
May 21

Deutsche Bank Remains a Hold on Novo Nordisk (0QIU)

TIPRANKS
·
May 20

Wegovy Liver Data Broadens Semaglutide Story For Novo Nordisk Investors

Simply Wall St.
·
May 20

Novo Nordisk Advances New Cagrilintide Study in the Race for Obesity Leadership

TIPRANKS
·
May 20

Novo Nordisk’s AMAZE 2 Trial: A New Weight-Loss Shot Targets Growth Beyond Semaglutide

TIPRANKS
·
May 20

Moderately bullish activity in Novo Nordisk with shares up 0.6%

TIPRANKS
·
May 19

Barclays Keeps Their Hold Rating on Novo Nordisk (0QIU)

TIPRANKS
·
May 19

Some people lose far more weight than others on GLP-1s like Wegovy. Here's why.

Dow Jones
·
May 19

PFE, NVO, LLY: Pharma Stocks Drop on News TrumpRx Set for ‘Dramatic Expansion’

TIPRANKS
·
May 19

Novo Nordisk A/S Stock Falls Monday, Underperforms Market

Dow Jones
·
May 19

Novo Nordisk Details Progress on DKK 15 Billion Share Buyback Programme

TIPRANKS
·
May 18

Big Pharma Firms Denied Certiorari by Supreme Court in Medicare Pricing Case

MT Newswires Live
·
May 18

Novo Nordisk Report Shows Bright Spots Amid Price Pressure -- Market Talk

Dow Jones
·
May 18

Novo Nordisk's Next Weight-Loss Battle: Winning Markets Beyond the U.S.

Deep News
·
May 18

Novo Nordisk Aims to Launch Oral Wegovy Weight-Loss Drug in Markets Beyond the U.S.

Deep News
·
May 18

Novo Nordisk’s Cagrilintide Trial Signals Next Wave in Obesity Treatment

TIPRANKS
·
May 16

Novo Nordisk Expands Obesity Pipeline With AMAZE 6 Knee Osteoarthritis Trial

TIPRANKS
·
May 16

Mixed options sentiment in Novo Nordisk with shares down 2.61%

TIPRANKS
·
May 16